Coherus Oncology (CHRS) Prepaid Assets (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Prepaid Assets data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Prepaid Assets fell 85.73% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 85.73% YoY), and the FY2025 full-year result was $6.8 million, up 2.21% from the prior year.
• Prepaid Assets eased to $2.3 million in Q1 2026, from $6.8 million in the prior quarter.
• In the past five years, Prepaid Assets ranged from a high of $21.0 million in Q1 2023 to a low of $2.3 million in Q1 2026.
• A 5-year average of $12.9 million and a median of $13.8 million in 2023 frame the typical range for Prepaid Assets.
• Across the five-year window, Prepaid Assets soared 105.49% in 2022 and plunged 85.73% in 2026, its largest moves.
• Tracing CHRS's Prepaid Assets over 5 years: stood at $17.9 million in 2022, then sank by 37.93% to $11.1 million in 2023, then plunged by 40.06% to $6.7 million in 2024, then increased by 2.21% to $6.8 million in 2025, then slumped by 66.57% to $2.3 million in 2026.
• Business Quant data shows CHRS's Prepaid Assets at $2.3 million in Q1 2026, $6.8 million in Q4 2025, and $8.7 million in Q3 2025.